Overview

The drug candidate REDECTANE® is based on an antibody and is being developed for the pre-surgical diagnosis of clear cell Renal Cell Cancer. REDECTANE® is the radioactively labelled form of the antibody WX-G250. The labelled antibody WX-G250 targets clear cell renal cell carcinoma and accumulates in the tumour tissue. This accumulation can be visualised by means of positron emission tomography (PET).

A proof-of-concept study with REDECTANE® was successfully conducted. It was shown that REDECTANE® could predict clear cell RCC with a specificity of 100 % and a sensitivity of 94 %. This means that the correct diagnosis with REDECTANE® that clear cell renal cell cancer is not present were confirmed by subsequent histology in 100 % (specificity). The correct diagnosis of clear cell renal cell cancer was confirmed in 94 % of cases (sensitivity). The Company is not aware of any other available imaging technique with comparable specificity and sensitivity.

The study was carried out by the cooperation partner of WILEX, the Ludwig Institute for Cancer Research, New York in collaboration with the Memorial Sloane-Kettering Cancer Center, New York.

REDECTANE® could determine whether the patient had clear cell renal cell carcinoma before surgery and the subsequent pathology. Therefore, REDECTANE® could significantly improve and simplify treatment planning for patients suspected of having renal cancer.